Administration of Gemcitabine for Metastatic Adenocarcinoma during Pregnancy: A Case Report and Review of the Literature

Abstract

We present the case of a 38-year-old woman diagnosed with metastatic adenocarcinoma of the biliary tract in the 18th week of pregnancy. Chemotherapy based on cisplatin and gemcitabine was administered, reaching disease stabilization until late-preterm delivery at 35 + 0 weeks of gestation. The infant was healthy and showed no malformations. Her head circumference was small, yet no neurological and behavioral defects have been detected. Development was normal during 14 months of follow-up. We discuss the implications of metastatic cancer in pregnancy with focus on therapeutic options for metastatic adenocarcinoma of the biliary tract. In this context, available data for the active regimens in biliary tract cancers—platinum compounds and gemcitabine—are discussed. This report is the fourth in the literature detailing the application of gemcitabine during pregnancy and the first presenting longer term follow-up, complementing available evidence that gemcitabine-based regimens are feasible in this situation.

Keywords

gemcitabine - pregnancy - adenocarcinoma - cholangiocarcinoma - chemotherapy

• References

• 1 Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist 2002; 7 (4) 279-287
• 2 Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. Lancet 2012; 379 (9815) 570-579
• 3 Amant F, Deckers S, Van Calsteren K , et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer 2010; 46 (18) 3158-3168
• 4 Morice P, Uzan C, Gouy S, Verschraegen C, Haie-Meder C. Gynaecological cancers in pregnancy. Lancet 2012; 379 (9815) 558-569
• 5 Evens AM, Advani RH, Lossos IS , et al. Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. Paper presented at: ASH Annual Meeting; San Diego; December 11, 2011
• 6 Azim Jr HA, Peccatori FA, Pavlidis N. Lung cancer in the pregnant woman: to treat or not to treat, that is the question. Lung Cancer 2010; 67 (3) 251-256
• 7 Amant F, Van Calsteren K, Halaska MJ , et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol 2012; 13 (3) 256-264
• 8 Benson III AB, Abrams TA, Ben-Josef E , et al. Hepatobiliary cancers clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009; 7 (4) 350-391
• 9 Romiti A, D'Antonio C, Zullo A , et al. Chemotherapy for the biliary tract cancers: moving toward improved survival time. J Gastrointest Cancer 2012; 43 (3) 396-404
• 10 de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999; 341 (18) 1368-1378
• 11 Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366 (9493) 1303-1314
• 12 Endo I, Gonen M, Yopp AC , et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248 (1) 84-96
• 13 Eckmann KR, Patel DK, Landgraf A , et al. Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointest Cancer Res 2011; 4 (5-6) 155-160
• 14 Furuse J, Kasuga A, Takasu A, Kitamura H, Nagashima F. Role of chemotherapy in treatments for biliary tract cancer. J Hepatobiliary Pancreat Sci 2012; 19 (4) 337-341
• 15 Sharma A, Dwary AD, Mohanti BK , et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010; 28 (30) 4581-4586
• 16 Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96 (6) 896-902
• 17 Yonemoto N, Furuse J, Okusaka T , et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007; 37 (11) 843-851
• 18 Valle J, Wasan H, Palmer DH , et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
• 19 Okusaka T, Nakachi K, Fukutomi A , et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103 (4) 469-474
• 20 Bohle W, Clemens P, Heubach T, Zoller W. Contrast-enhanced ultrasound (CEUS) for differentiating between hepatocellular and cholangiocellular carcinoma. Ultraschall Med - Eur J Ultrasound 2011; 33: 191-195
• 21 Hainsworth JD, Rubin MS, Spigel DR , et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 2013; 31 (2) 217-223
• 22 Purtilo DT, Clark JV, Williams R. Primary hepatic malignancy in pregnant women. Am J Obstet Gynecol 1975; 121 (1) 41-44
• 23 Devoe LD, Moossa AR, Levin B. Pregnancy complicated by extrahepatic biliary tract carcinoma. A case report. J Reprod Med 1983; 28 (2) 153-155
• 24 Balderston KD, Tewari K, Azizi F, Yu JK. Intrahepatic cholangiocarcinoma masquerading as the HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) in pregnancy: case report. Am J Obstet Gynecol 1998; 179 (3 Pt 1) 823-824
• 25 Sadoon S, Hodgett S. Unusual cause of itching in a pregnancy (cholangiocarcinoma). J Obstet Gynaecol 2008; 28 (2) 230-231
• 26 Marasinghe JP, Karunananda SA, Angulo P. Cholangiocarcinoma in pregnancy: a case report. J Obstet Gynaecol Res 2008; 34 (4 Pt 2) 635-637
• 27 Mir O, Berveiller P, Ropert S, Goffinet F, Goldwasser F. Use of platinum derivatives during pregnancy. Cancer 2008; 113 (11) 3069-3074
• 28 Gensheimer M, Jones CA, Graves CR, Merchant NB, Lockhart AC. Administration of oxaliplatin to a pregnant woman with rectal cancer. Cancer Chemother Pharmacol 2009; 63 (2) 371-373
• 29 Cerqueira NMFSA, Fernandes PA, Ramos MJ. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry 2007; 13 (30) 8507-8515
• 30 Esumi Y, Mitsugi K, Seki H, Takao A, Kawai M. Placental transfer, lacteal transfer and plasma protein binding of gemcitabine. Xenobiotica 1994; 24 (10) 957-964
• 31 Eudaly JA, Tizzano JP, Higdon GL, Todd GC. Developmental toxicity of gemcitabine, an antimetabolite oncolytic, administered during gestation to CD-1 mice. Teratology 1993; 48 (4) 365-381
• 32 Kim JH, Kim HS, Sung CW, Kim KJ, Kim CH, Lee KY. Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy. Lung Cancer 2008; 59 (2) 270-273
• 33 Gurumurthy M, Koh P, Singh R , et al. Metastatic non-small-cell lung cancer and the use of gemcitabine during pregnancy. J Perinatol 2009; 29 (1) 63-65
• 34 Boyd CA, Benarroch-Gampel J, Kilic G, Kruse EJ, Weber SM, Riall TS. Pancreatic neoplasms in pregnancy: diagnosis, complications, and management. J Gastrointest Surg 2012; 16 (5) 1064-1071